203 related articles for article (PubMed ID: 27092864)
1. Successful treatment of multiple vemurafenib-induced keratoacanthomas by topical application of imiquimod cream: Confirmation of clinical clearance by dermoscopy.
Rhee do Y; Won KH; Lee YJ; Won CH; Chang SE; Lee MW
J Dermatolog Treat; 2016 Oct; 27(5):448-9. PubMed ID: 27092864
[TBL] [Abstract][Full Text] [Related]
2. Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma.
Alloo A; Garibyan L; LeBoeuf N; Lin G; Werchniak A; Hodi FS; Flaherty KT; Lawrence DP; Lin JY
Arch Dermatol; 2012 Mar; 148(3):363-6. PubMed ID: 22431777
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
Sinha R; Larkin J; Gore M; Fearfield L
Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous adverse events during vemurafenib therapy.
Chandrakumar SF; Yeung J
J Cutan Med Surg; 2014; 18(4):223-8. PubMed ID: 25008438
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
[TBL] [Abstract][Full Text] [Related]
6. [Adverse skin reactions induced by BRAF inhibitors: a systematic review].
Sibaud V; Lamant L; Maisongrosse V; Delord JP
Ann Dermatol Venereol; 2013; 140(8-9):510-20. PubMed ID: 24034635
[TBL] [Abstract][Full Text] [Related]
7. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.
Chu EY; Wanat KA; Miller CJ; Amaravadi RK; Fecher LA; Brose MS; McGettigan S; Giles LR; Schuchter LM; Seykora JT; Rosenbach M
J Am Acad Dermatol; 2012 Dec; 67(6):1265-72. PubMed ID: 22609219
[TBL] [Abstract][Full Text] [Related]
8. Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.
Johnson DB; Wallender EK; Cohen DN; Likhari SS; Zwerner JP; Powers JG; Shinn L; Kelley MC; Joseph RW; Sosman JA
Cancer Immunol Res; 2013 Dec; 1(6):373-7. PubMed ID: 24490176
[TBL] [Abstract][Full Text] [Related]
9. Reduced expression of the ATP2A2 gene in vemurafenib-induced keratoacanthoma-like papules in a melanoma patient.
Wakimoto H; Harada K; Arai T; Maeda T; Irisawa R; Tsuboi R
Int J Dermatol; 2017 Feb; 56(2):e33-e35. PubMed ID: 27805257
[No Abstract] [Full Text] [Related]
10. Dermatological approach to vemurafenib skin toxicity: a single centre experience.
Fava P; Marra E; Astrua C; Brizio M; Cavaliere G; Quaglino P; Fierro MT; Savoia P
G Ital Dermatol Venereol; 2016 Feb; 151(1):25-31. PubMed ID: 25296968
[TBL] [Abstract][Full Text] [Related]
11. Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation.
Lheure C; Kramkimel N; Franck N; Laurent-Roussel S; Carlotti A; Queant A; Goldwasser F; Avril MF; Dupin N
Dermatology; 2015; 231(4):378-84. PubMed ID: 26452227
[TBL] [Abstract][Full Text] [Related]
12. Spontaneous regression of keratoacanthoma can be promoted by topical treatment with imiquimod cream.
Di Lernia V; Ricci C; Albertini G
J Eur Acad Dermatol Venereol; 2004 Sep; 18(5):626-9. PubMed ID: 15324413
[TBL] [Abstract][Full Text] [Related]
13. A novel therapeutic combination approach for treating multiple vemurafenib-induced keratoacanthomas: systemic acitretin and intralesional fluorouracil.
LaPresto L; Cranmer L; Morrison L; Erickson CP; Curiel-Lewandrowski C
JAMA Dermatol; 2013 Mar; 149(3):279-81. PubMed ID: 23552479
[No Abstract] [Full Text] [Related]
14. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma.
Bong AB; Bonnekoh B; Franke I; Schön M; Ulrich J; Gollnick H
Dermatology; 2002; 205(2):135-8. PubMed ID: 12218228
[TBL] [Abstract][Full Text] [Related]
15. Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
Sufficool KE; Hepper DM; Linette GP; Hurst EA; Lu D; Lind AC; Cornelius LA
J Cutan Pathol; 2014 Jul; 41(7):568-75. PubMed ID: 24641301
[TBL] [Abstract][Full Text] [Related]
16. A case of vemurafenib-induced keratosis pilaris-like eruption.
Wang CM; Fleming KF; Hsu S
Dermatol Online J; 2012 Apr; 18(4):7. PubMed ID: 22559022
[TBL] [Abstract][Full Text] [Related]
17. Clearance of BRAF inhibitor-associated keratoacanthomas by systemic retinoids.
Sachse MM; Wagner G
Br J Dermatol; 2014 Feb; 170(2):475-7. PubMed ID: 24117280
[No Abstract] [Full Text] [Related]
18. Vemurafenib-induced eccrine squamous syringometaplasia.
Lescoat A; Droitcourt C; Stock N; Le Gall F; Dupuy A
Dermatology; 2013; 226(4):362-4. PubMed ID: 23860306
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Outcomes of Melanoma In Situ Treated With Topical 5% Imiquimod Cream: A Retrospective Review.
Park AJ; Paul J; Chapman MS; Samie FH
Dermatol Surg; 2017 Aug; 43(8):1017-1022. PubMed ID: 28328708
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream.
Ray CM; Kluk M; Grin CM; Grant-Kels JM
Int J Dermatol; 2005 May; 44(5):428-34. PubMed ID: 15869545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
